Osteoboost and Midi Health to Host Free Webinar on HRT and Bone Density for Women in Menopause

Osteoboost Health, Inc. and Midi Health will co-host a free public webinar, HRT and the New Science of Strong Bones, on Thursday, April 16, 2026, at 2 p.m. PT (5 p.m. ET). Hosted by Osteoboost CEO Laura Yecies and moderated by Osteoboost Chief Medical Officer Dr. Pamela Peeke, the one-hour live event will feature Midi Health Chief Clinical Officer Dr. Mindy Goldman in a fireside chat on the latest science behind how hormone replacement therapy (HRT) affects bone density during perimenopause and menopause.

Event Overview

Despite growing awareness of menopause, bone health remains one of the most underaddressed areas of women’s long-term care. Bone loss accelerates significantly at the onset of perimenopause due to declining estrogen levels, yet it rarely produces symptoms until significant damage has occurred. With the HRT black box warning lifted last fall, hormone replacement therapy has become a leading topic in women’s health, not only for managing menopause symptoms but for its protective effects on long-term bone density.

Dr. Goldman and Dr. Peeke will cover:

• Why bone density begins to decline at perimenopause, and how estrogen loss accelerates bone loss during menopause and beyond
• How different HRT delivery methods compare in their effects on bone health, and how to evaluate which may be most appropriate for each patient
• Who is a candidate for HRT, including those more than 10 years post-menopause or with a history of heart disease or breast cancer
• How to talk to your doctor about HRT as part of a holistic bone protection plan that includes nutrition, exercise, and the Osteoboost prescription vibration therapy device

Speakers

• Dr. Mindy Goldman, Chief Clinical Officer, Midi Health, is a Clinical Professor in OB/GYN at UCSF, a nationally recognized expert in menopause care, and chair of the menopause panel for the National Comprehensive Cancer Network (NCCN).
  
  
• Dr. Pamela Peeke, Chief Medical Officer, Osteoboost Health, is a Pew Foundation Scholar, Assistant Professor of Medicine at the University of Maryland, and a former NIH senior research fellow with expertise in menopause, bone health, and preventive medicine for women.
• Laura Yecies, CEO, Osteoboost Health, is a serial technology and digital health executive with more than 30 years of leadership experience, including previous CEO roles at SugarSync, Catch, and Neurosync.

Event Details:

• Date: Thursday, April 16, 2026
• Time: 2:00 p.m. PT / 5:00 p.m. ET
• Format: Free, live webinar via Zoom with live Q&A
• Registration: https://us06web.zoom.us/webinar/register/3317736823559/WN__2ifNgXKRgyJraWqWJiFmQ

About Osteoboost Health, Inc.

Osteoboost Health is a Redwood City-based company that applies science and medical expertise to create better health outcomes for women and men at risk of osteoporosis and bone fractures. The company’s first FDA-approved device, Osteoboost, is poised to become the new standard of care in treating postmenopausal osteopenia. Osteoboost Health is backed by leading investors, including Esplanade Ventures, Terumo Medical Corporation, Ambit Health Ventures, Good Growth Capital, Portfolia, Astia Angels, AARP, and Golden Seeds. For more information about Osteoboost, including the full Indications for Use, please visit www.osteoboost.com.

About Midi Health

Midi Health is setting a new standard for healthcare. As the nation’s fastest-growing women’s telehealth company, Midi provides accessible, insurance-covered services in all 50 states – designed by world-class medical experts. Building on its leadership in perimenopause and menopause, Midi fills the critical health gaps women face at every age and life stage.

Contact Information

VSC for Osteoboost

PR for Osteoboost

VSC

osteoboost@vsc.co